Loading cancer entity…
Loading cancer entity…
Clinical trials
81 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (10)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07842055 | AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma | completed | — | 3,648 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk | terminated | Phase 2 | 65 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07408856 | CAN1012 in Pre-Malignant DCIS and LCIS | recruiting | Phase 1 | 24 | Providence Health & ServicesOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07020806 | [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC) | recruiting | Phase 1 | 30 | University of California, DavisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06033092 | Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion(TOLERANT) | completed | Phase 2 | 110 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03317405 | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | active not recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05837767 | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05964504 | Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) | recruiting | — | 150 | University of California, San FranciscoOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06671912 | Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial(LoTam) | suspended | Phase 3 | 1,556 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07613151 | Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study(NAPOLI) | recruiting | — | 250 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06067503 | Biomarkers to Detect Endocrine Therapy Resistance | recruiting | Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05919108 | Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | recruiting | Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07229417 | A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06184750 | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06557148 | A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer | active not recruiting | — | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05931302 | Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT(GALILEE) | active not recruiting | N/A | 40 | Centre Hospitalier Intercommunal de Toulon La Seyne sur MerOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05941520 | Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer | recruiting | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02515110 | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer | active not recruiting | N/A | 137 | Virginia Commonwealth UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05178498 | Impact of Dietary Inflammatory Potential on Breast Cancer Risk | recruiting | — | 960 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05982496 | 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer(FESTA) | recruiting | Phase 2 | 119 | Università Vita-Salute San RaffaeleOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03936478 | Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer(MAPBI) | recruiting | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07635654 | Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses(DELILA) | not yet recruiting | N/A | 43 | KU LeuvenOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT01953588 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | active not recruiting | Phase 3 | 1,473 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jun 5, 2026 | clinicaltrials |
| NCT07483307 | A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | recruiting | Phase 2 | 176 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05755269 | Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women | terminated | — | 19 | Mayo ClinicOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01905046 | Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | active not recruiting | Phase 3 | 86 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07527468 | HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery(HISMAR) | not yet recruiting | N/A | 228 | Hôpital du ValaisOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease(TBCRC042) | completed | Phase 2 | 84 | Julie NangiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04496739 | Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE) | active not recruiting | N/A | 412 | SWOG Cancer Research NetworkNETWORK | 2 | Apr 7, 2026 | clinicaltrials |
| NCT06133465 | Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management | completed | — | 1,063 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06133647 | Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System | completed | — | 8 | Methodist Health SystemOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03868475 | Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions(VAPEX) | withdrawn | N/A | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | active not recruiting | Phase 3 | 898 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06666439 | Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer(LBC-Monitor) | recruiting | — | 20 | Julia FoldiOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07313033 | [68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).(FAPI-CL) | not yet recruiting | N/A | 45 | Hospices Civils de LyonOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04206891 | CDH1 Germline Mutations in Lobular Breast Cancer | completed | — | 421 | European Institute of OncologyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05410951 | LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients(LobularCard) | active not recruiting | — | 800 | European Institute of OncologyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | terminated | Phase 2 | 26 | Mayo ClinicOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours(ROLo) | completed | Phase 2 | 33 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT01819233 | Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy(CAREFOR) | completed | N/A | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | terminated | Phase 2 | 44 | University of UtahOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT05086705 | EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer | completed | N/A | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04750473 | Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer | completed | Phase 1 | 20 | Emory UniversityOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04551495 | Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)(ROSALINE) | unknown | Phase 2 | 65 | Jules Bordet InstituteOTHER | 2 | Dec 4, 2024 | clinicaltrials |
| NCT05960201 | Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma | completed | Phase 2 | 23 | Asan Medical CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials